Soquelitinib Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated:

The clinical evidence base for Soquelitinib comprises 1 peer-reviewed publications across 1 journals, 0 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Autoimmune Lymphoproliferative Syndrome. Most recent publication: Natural history of autoimmune lymphoproliferative syndrome associated with FAS gene mutations., Blood, 2014.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

  1. Natural history of autoimmune lymphoproliferative syndrome associated with FAS gene mutations.
    Price S, Shaw PA, Seitz A, et al. · Blood · 2014
    PubMed: PMID 24398331 · NCT06730126 · Autoimmune Lymphoproliferative Syndrome

Publications by year

2014–2014: 1 publications.

2014
1

Publications by indication

Autoimmune Lymphoproliferative Syndrome (1)

  • Natural history of autoimmune lymphoproliferative syndrome associated with FAS gene mutations.
    Blood · 2014 · PMID 24398331 · NCT06730126

Publications by journal

All Soquelitinib publications (1)

2014 (1 paper)

  1. Natural history of autoimmune lymphoproliferative syndrome associated with FAS gene mutations.
    Price S, Shaw PA, Seitz A, et al. · Blood · 2014 · Background
    PubMed: PMID 24398331 · NCT06730126 · Autoimmune Lymphoproliferative Syndrome

Sources and methodology

This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).